Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAR-M-C-MET for Advanced Pancreatic Cancer
NCT07553793Phase 1Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2026
- Primary completion
- Dec 2028
- Modality
- CAR-Macrophages
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CAR-M-C-MET in pancreatic cancer (PC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days and Objective Response Rate up to 96 weeks. Planned start May 2026; status: not yet recruiting.
02
Drugs
CAR-M-C-MET
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07553793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07553793.